September 21, 2017 / 4:31 PM / a year ago

FDA warns of liver injury, death risks from Intercept's drug

Sept 21 (Reuters) - The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc’s drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

The U.S. drugmaker’s shares fell 8.7 percent to $89.54 in afternoon trading.

Ocaliva, approved last May, is used to treat primary biliary cholangitis, a rare, chronic liver disease that causes bile ducts in the liver to become inflamed, damaged and destroyed.

The FDA said some patients were receiving higher doses of Ocaliva, particularly due to a higher frequency of dosing than recommended in the drug label. (

Intercept had sent a letter earlier this month to healthcare providers with prescribing information for the drug, and flagged reports of liver failure and deaths. ( (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below